PUMA BIOTECHNOLOGY INC (PBYI) competitors & alternatives
Health Care · NASDAQ
PUMA BIOTECHNOLOGY INC (PBYI)'s top competitors and alternatives — its most similar public companies — include Pfizer (PFE), ALX ONCOLOGY HOLDINGS INC (ALXO), CELCUITY INC (CELC), OLEMA PHARMACEUTICALS INC (OLMA), GREENWICH LIFESCIENCES INC (GLSI), ONKURE THERAPEUTICS INC CLASS A (OKUR), BridgeBio Oncology Therapeutics, Inc. (BBOT), NUVECTIS PHARMA INC (NVCT), NUVALENT INC CLASS A (NUVL), ARVINAS INC (ARVN), ZYMEWORKS INC (ZYME) and VERACYTE INC (VCYT). These are PUMA BIOTECHNOLOGY INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top PBYI competitors & alternatives
-
PfizerPFEHealth Care
Global biopharmaceutical company discovering, developing, and manufacturing prescription medicines and vaccines across oncology, immunology, cardiovascular,…
$24.82 (as of 2026-07-22) · market cap $142.0B
-
ALX ONCOLOGY HOLDINGS INCALXOHealth Care
An early-stage immuno-oncology biotech advancing a next-generation CD47 blocker designed to restore macrophage tumor-killing when combined with targeted cancer…
$2.02 (as of 2026-07-22) · market cap $272M
-
CELCUITY INCCELCHealth Care
Celcuity is developing gedatolisib, a comprehensive PI3K/AKT/mTOR pathway inhibitor in Phase 3 trials for hormone receptor-positive breast cancer and…
$90.14 (as of 2026-07-22) · market cap $4.4B
-
OLEMA PHARMACEUTICALS INCOLMAHealth Care
Olema Pharmaceuticals is developing next-generation targeted therapies, including a dual-action CERAN/SERD, to transform the treatment of endocrine-driven…
$11.49 (as of 2026-07-22) · market cap $1.0B
-
GREENWICH LIFESCIENCES INCGLSIHealth Care
Greenwich LifeSciences develops GLSI-100, an immunotherapy combining a HER2/neu-targeting peptide and GM-CSF to prevent breast cancer recurrence after surgery.
$13.27 (as of 2026-07-22) · market cap $195M
-
ONKURE THERAPEUTICS INC CLASS AOKURHealth Care
OnKure Therapeutics is a clinical-stage biotech developing precision small molecule drugs that selectively target mutated proteins to treat cancer and vascular…
$4.32 (as of 2026-07-22) · market cap $175M
-
BridgeBio Oncology Therapeutics, Inc.BBOTHealth Care
BridgeBio Oncology is advancing next-generation small-molecule inhibitors of RAS and PI3K pathways for previously untreatable solid tumors including…
$8.90 (as of 2026-07-22) · market cap $701M
-
NUVECTIS PHARMA INCNVCTHealth Care
Nuvectis is an early-stage oncology biotech developing NXP900, a novel SRC/YES1 kinase inhibitor designed to overcome drug resistance in solid tumors including…
$19.29 (as of 2026-07-22) · market cap $608M
-
NUVALENT INC CLASS ANUVLHealth Care
Nuvalent is a clinical-stage precision oncology company developing targeted kinase inhibitors to address the challenges of treatment resistance and off-target…
$123.96 (as of 2026-07-21) · market cap $9.8B
-
ARVINAS INCARVNHealth Care
Arvinas is a pioneer in targeted protein degradation, utilizing its PROTAC platform to develop small molecule therapeutics that eliminate disease-causing…
$8.26 (as of 2026-07-22) · market cap $536M
-
ZYMEWORKS INCZYMEHealth Care
A biotech company pioneering multispecific antibodies and ADCs for cancer and autoimmune disease, monetizing through a partnership-driven royalty aggregation…
$23.36 (as of 2026-07-22) · market cap $1.7B
-
VERACYTE INCVCYTHealth Care
Veracyte is a genomics-focused diagnostics company providing high-value clinical tests to improve cancer detection and treatment guidance for patients…
$58.01 (as of 2026-07-22) · market cap $4.8B
Not quite? Describe exactly what you want →
Peers are PUMA BIOTECHNOLOGY INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: PUMA BIOTECHNOLOGY INC (PBYI).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.